BG104730A - Method for producing 5-lipooxygenase inhibitors having different heterocyclic ring systems - Google Patents

Method for producing 5-lipooxygenase inhibitors having different heterocyclic ring systems

Info

Publication number
BG104730A
BG104730A BG104730A BG10473000A BG104730A BG 104730 A BG104730 A BG 104730A BG 104730 A BG104730 A BG 104730A BG 10473000 A BG10473000 A BG 10473000A BG 104730 A BG104730 A BG 104730A
Authority
BG
Bulgaria
Prior art keywords
formula
naoh
koh
produced
strong base
Prior art date
Application number
BG104730A
Other languages
Bulgarian (bg)
English (en)
Inventor
Timothy Norris
Megan HNATOW
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG104730A publication Critical patent/BG104730A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BG104730A 1999-08-31 2000-08-29 Method for producing 5-lipooxygenase inhibitors having different heterocyclic ring systems BG104730A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161099P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
BG104730A true BG104730A (en) 2001-09-28

Family

ID=22539510

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104730A BG104730A (en) 1999-08-31 2000-08-29 Method for producing 5-lipooxygenase inhibitors having different heterocyclic ring systems

Country Status (33)

Country Link
EP (1) EP1081144A3 (cs)
JP (1) JP2001106686A (cs)
KR (1) KR20010050274A (cs)
CN (1) CN1286251A (cs)
AP (1) AP2000001909A0 (cs)
AR (1) AR022650A1 (cs)
AU (1) AU5370200A (cs)
BG (1) BG104730A (cs)
BR (1) BR0003888A (cs)
CA (1) CA2316748A1 (cs)
CO (1) CO5180623A1 (cs)
CZ (1) CZ20003159A3 (cs)
EA (1) EA200000803A3 (cs)
EE (1) EE200000513A (cs)
GT (1) GT200000144A (cs)
HR (1) HRP20000565A2 (cs)
HU (1) HUP0003437A3 (cs)
ID (1) ID27128A (cs)
IL (1) IL138089A0 (cs)
IS (1) IS5604A (cs)
MA (1) MA26750A1 (cs)
NO (1) NO20004312L (cs)
NZ (1) NZ506633A (cs)
OA (1) OA11451A (cs)
PA (1) PA8499601A1 (cs)
PE (1) PE20010523A1 (cs)
PL (1) PL342280A1 (cs)
SG (1) SG87145A1 (cs)
SK (1) SK12862000A3 (cs)
SV (1) SV2002000160A (cs)
TN (1) TNSN00176A1 (cs)
TR (1) TR200002530A2 (cs)
UY (1) UY26315A1 (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188557A1 (en) * 2003-05-23 2006-08-24 Hisamitsu Pharmaceutical Co., Inc. Prepartaion for external percutaneous administration containing non-steroidal anti-inflammatory drug and interleukin-1 alpha production inhibitor
US7674811B2 (en) 2006-03-14 2010-03-09 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
CN103980312B (zh) * 2014-05-27 2016-09-07 广州大学 一种n杂环双膦配体及其合成方法
WO2025038927A1 (en) * 2023-08-16 2025-02-20 Raythera, Inc. Modulators of tnf alpha activity and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281577B6 (sk) * 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze

Also Published As

Publication number Publication date
EE200000513A (et) 2001-04-16
CZ20003159A3 (cs) 2001-12-12
HUP0003437A3 (en) 2002-08-28
EP1081144A3 (en) 2001-04-11
OA11451A (en) 2003-12-08
SG87145A1 (en) 2002-03-19
CA2316748A1 (en) 2001-02-28
HUP0003437A2 (hu) 2001-06-28
IS5604A (is) 2001-03-01
SK12862000A3 (sk) 2002-02-05
MA26750A1 (fr) 2004-12-20
PE20010523A1 (es) 2001-04-28
NO20004312L (no) 2001-03-01
KR20010050274A (ko) 2001-06-15
SV2002000160A (es) 2002-01-23
JP2001106686A (ja) 2001-04-17
IL138089A0 (en) 2001-10-31
UY26315A1 (es) 2001-04-30
BR0003888A (pt) 2001-12-11
EA200000803A3 (ru) 2001-06-25
TR200002530A2 (tr) 2001-04-20
HRP20000565A2 (en) 2001-06-30
EA200000803A2 (ru) 2001-04-23
NZ506633A (en) 2001-12-21
TNSN00176A1 (fr) 2005-11-10
AR022650A1 (es) 2002-09-04
NO20004312D0 (no) 2000-08-30
AU5370200A (en) 2001-03-08
ID27128A (id) 2001-03-01
PA8499601A1 (es) 2002-02-21
CN1286251A (zh) 2001-03-07
HU0003437D0 (en) 2000-08-30
GT200000144A (es) 2002-02-20
EP1081144A2 (en) 2001-03-07
AP2000001909A0 (en) 2000-09-30
PL342280A1 (en) 2001-03-12
CO5180623A1 (es) 2002-07-30

Similar Documents

Publication Publication Date Title
Irving et al. 637. The stability of transition-metal complexes
Jaganyi et al. Controlling the Lability of Square-Planar Pt (II) Complexes through Electronic Communication between pi-Acceptor Ligands This work was supported by the Deutsche Forschungsgemeinschaft, Fonds der Chemischen Industrie, and the Alexander von Humboldt Foundation (fellowship to DJ)
EP1026222A3 (en) Organic material for electroluminescent device and electroluminescent device using the same
GB9928290D0 (en) Process for preparing ambient temperature ionic liquids
HUP0202597A2 (en) Mixture of two particulate phases used in the production of a green compact that can be sintered at higher temperatures
BG105035A (en) Method for preparing alkoxyamines from nitroxides
CA2167388A1 (en) Bitetrazoleamine Gas Generant Compositions and Methods of Use
PL320138A1 (en) Method of and solution for obtaining a conversive coating on metal surface
Gambs et al. Ligand Electronic Effect in Enantioselective Palladium-Catalyzed Copolymerization of Carbon Monoxide and Propene This work was supported by the ETH Zürich. We thank Novartis AG and Solvias AG, Basel, for the donation of chemicals
BG104730A (en) Method for producing 5-lipooxygenase inhibitors having different heterocyclic ring systems
DE59501328D1 (de) Gaserzeugende Mischung
ZA956032B (en) Method of preparing powders for hard materials from APT and soluble cobalt salts
EP1285902A4 (en) TRITIUM MARKING PROCESS
CA2171715A1 (en) Gold lixiviation using nitrogen and sulfur heterocyclic aromatic compounds
IL114676A0 (en) Methods for preparing multicarbide powders for hard materials
WO1999010315A3 (de) Verfahren zur herstellung von 2-cyanoindan-1-onen
Forschner et al. Carbon dioxide activation as an η 1-C metallocarboxylate: metallocarboxylate ester derivatives as a C 1 template in co-ordinated ligand reactions
Kandaz et al. A water-soluble multisite ionophore ligand bearing pyridine and aminothiophenol functionality. Synthesis, spectroscopy and electrochemistry of its complexes, and peripheral reactivity of the (E, E) M (M= Ni) complex with Pd2+ and Ag+
YU52800A (sh) Postupak za dobijanje inhibitora 5-lipoksigenaze koji imaju različite heterociklične prstenaste sisteme
EP0307179A3 (en) Mitomycins and processes for their preparation
CA2274356A1 (en) Method for doping and coating nickel hydroxide
El Dien et al. Structure identification of 2-thiohydantoin and its metal chelates by thermal and spectral analysis
Xiao-jun et al. Coordination compounds of bis [(1-cinnamoylhydrazonoethyl) cyclopentadienyl] iron lanthanide
WO1998002236A3 (en) Method of supported metal catalyst production
Morrissey Bright Palladium Electrodeposition